Sirius Therapeutics

Shanghai, China · Founded 2022 · In IPO Registration

Developer and researcher of novel RNAi therapies intended to treat chronic diseases. Sirius Therapeutics is based in Shanghai, China and was founded in 2022. Its last reported valuation was $253 million in May 2025. It has raised $214 million.

Last reported valuation
$252.5M
Oct 2026
Priced at
—
Total raised
$214.0M
Last round
—

Who backs Sirius Therapeutics?

7 investors
InvestorType
OrbiMedGrowth equity
Hankang CapitalVenture capital
Image Frame InvestmentOther
BioTrack Capital—
CRISPR Therapeutics—
Creacion Ventures—
Delos Capital Partners—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Sirius Therapeutics investors

7 investors are on record for Sirius Therapeutics, including OrbiMed, Hankang Capital, Image Frame Investment and BioTrack Capital.

Free account
More of Sirius Therapeutics with a free account
  • ·Watch Sirius Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 7 firms already write checks for companies like Sirius Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View